Utilizing the ELISpot Assay to Quantify T Cell Responses in AAV Gene Therapy
Time: 9:30 am
day: Conference Day One
Details:
- Navigating the complex logistics of the ELISpot assay to ensure viable T cells are analyzed
- Discussing the use of the ELISpot assays at different stages of development
- Preclinical: assessing immunogenicity of AAV vectors
- Clinical: monitoring for T cell-mediated rejection of AAV gene therapy
- Optimizing capsid design and selecting capsids to minimize immune response
- Addressing potential solutions to mitigate the limitations of the ELISpot assay
